Reliable Quality

Affordable Innovation

Research Progress

Until now, in addition to one product launched commercially and two products under NDA/MAA review, Henlius has conducted over 20 clinical studies for 10 products and 8 combination therapies worldwide. HLX01 (汉利康®, rituximab injection), the first product of Henlius, has been granted approval by the NMPA as the first approved biosimilar in China, which also makes it the first commercially launched monoclonal antibody biosimilar in accordance with the Biosimilar Guidelines in China.

Products in R&D
Generic Name
Study Phase
Potential Indication
Study Phase
Product Pipeline

With our efficient and innovative in-house capabilities, we have developed a diversified and advanced drug pipeline with a focus in the fields of oncology, autoimmune diseases etc. 

                                 Last Updated: April, 2020